Obstructive Lung Disease

Antifibrinolytic Therapy Reduces Hemoptysis in Adults With Cystic Fibrosis

Systemic antifibrinolytic therapy in adult patients with cystic fibrosis has been associated with a reduced rate of hospital admissions for hemoptysis.

Biomarkers of Pancreatic Function in CF Improved With Lumacaftor/Ivacaftor

Improvements in pancreatic function biomarkers, including increases in fecal elastase-1 and decreases in serum immunoreactive trypsinogen, were seen in patients treated with lumacaftor and ivacaftor.

Buying Time to First Exacerbation in Non-Cystic Fibrosis Bronchiectasis

Inhaled liposomal ciprofloxacin is associated with a longer median time to first pulmonary exacerbation vs placebo in patients with non-cystic fibrosis bronchiectasis and chronic P aeruginosa lung infection requiring antibiotic therapy.

Cystic Fibrosis May Be a Risk Factor for Hemiplegic Migraine and Stroke

Due to brain excitability and hypoxia from coughing, patients with cystic fibrosis have a propensity for cortical spreading depression and hemiplegic migraine.

Bronchiectasis Severity Associated With Pulmonary Vascular Pruning

Mild bronchiectasis in smokers is associated with distal pulmonary vascular pruning.

Multiple Breath Washout Test Inaccuracies Revealed Via Over-Reader Assessment

Including invalid data decreases the validity of multiple breath washout measurements in clinical trials involving adults with bronchiectasis.

VX-445-Tezacaftor-Ivacaftor May Improve CFTR in Cystic Fibrosis

VX-445-tezacaftor-ivacaftor led to noticeable improvements in Phe508del CFTR protein function.

Cystic Fibrosis Lung Function Improved With Triple Therapy

Adding VX-659 to tezacaftor and ivacaftor therapy improved lung function in patients with cystic fibrosis.